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Abstract
Background: Information on epidemiology of atrial fibrillation (AF) in Middle European 
Countries such as Poland is limited.
Methods: We studied 1,556 patients with AF. We focused on different types of AF in terms of 
clinical features and management.
Results: CHA2DS2-VASc score was 3.5 ± 1.7 and HAS-BLED score — 2.4 ± 1.1. In-hospital 
mortality was 2%. The CHA2DS2-VASc score was the highest in permanent AF (p < 0.001) 
and the HAS-BLED score was the highest in paroxysmal and permanent AF (p < 0.001). The 
CHA2DS2-VASc score ≥ 2 was found in the majority of non-valvular AF patients. Permanent 
AF was associated with the highest thromboembolic risk (p < 0.001). Valvular AF was more 
commonly observed in patients with permanent AF (p = 0.004). Seventy-one percent of pa-
tients who had CHA2DS2-VASc > 2 received antithrombotic therapy. Acetylsalicylic acid alone 
was most common in paroxysmal AF (p < 0.001). Patients with valvular AF had more often 
permanent AF (p < 0.004). Valvular AF patients were more often prescribed antithrombotic 
therapy (p = 0.001). The in-hospital mortality did not differ between patients with valvular 
and non-valvular AF (p = 0.3). In multivariate logistic regression, odds of in-hospital death 
were higher for patients > 75 years old (OR = 6.26, p = 0.001, 95% CI 2.06–19.02) and with 
ejection fraction < 35% (OR = 5.25, p < 0.001, 95% CI 2.24–12.32).
Conclusions: Our population with AF have similar risk of stroke and bleeding as in Euro-
pean registries. The need for anticoagulation in AF patients is well established in daily medical 
care in Poland similarly to Western Europe. Patients with valvular AF are more frequently 
prescribed antithrombotic therapy than patients with non-valvular AF. In-hospital mortality 
is relatively low in both valvular and non-valvular AF patients and is connected with old age 
and diminished ejection fraction. (Cardiol J 2015; 22, 3: 296–305)
Key words: valvular atrial fibrillation, non-valvular atrial fibrillation
ORIGINAL ARTICLE
Cardiology Journal 
2015, Vol. 22, No. 3, 296–305
DOI: 10.5603/CJ.a2014.0083
Copyright © 2015 Via Medica
ISSN 1897–5593
296 www.cardiologyjournal.org
Address for correspondence: Anna Tomaszuk-Kazberuk, MD, PhD, Department of Cardiology, University Hospital  
in Bialystok, ul. Skłodowska-Curie 24A, 15–276 Białystok, Poland, tel: +48 85 746 86 56, fax: +48 85 746 86 04,  
e-mail: walkaz@poczta.fm
Received: 24.07.2014 Accepted: 21.09.2014
Introduction
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia, occurring in 1–2% of the gen-
eral population and is a well known risk factor of 
cardiovascular morbidity and mortality [1]. In 2010 
and 2012, the guidelines of the European Society of 
Cardiology on the management of AF were released 
as a consequence of well controlled randomized 
trials such as RELY, ROCKET and ARISTOTLE 
[1–5]. On the other hand, there is an increasing 
number of national registries describing prevalence 
of AF, co-morbidities, stroke risk factors and an-
tithrombotic therapy in real life conditions [6, 7]. 
Data from 7 representative Western European 
countries illustrating changes in the management 
of AF have been recently published [8]. Informa-
tion on epidemiology of AF in Middle European 
Countries such as Poland is limited. Moreover, data 
on valvular AF patients are very scant.
This is the first real life report on character-
istics and management of the patients with AF 
including valvular AF patients from Reference 
Cardiology University Center in Bialystok, Poland.
Methods
Study population
We retrospectively studied 1,556 patients with 
the diagnosis of AF hospitalized in the Department of 
Cardiology and Department of Invasive Cardiology in 
years 2012–2014. No exclusion criteria were defined 
to avoid biased selection of patients and achieve 
a cohort close to real life. At the study entry medical 
history was recorded, all patients underwent physical 
examination, resting electrocardiography (ECG), and 
routine transthoracic echocardiography. The study 
protocol conformed to the ethical guidelines of the 
1975 Declaration of Helsinki, and was approved by 
the local Ethics Committee.
In the analysis, we focused on different types 
of AF in terms of clinical features and management.
Definitions of valvular AF, chronic kidney 
disease, chronic heart failure, anemia and 
ischemic heart disease
We define valvular AF according to recent 2014 
AHA/ACC/HRS guideline for the management of 
patients with AF [9] as AF in rheumatic mitral 
stenosis, a mechanical or bioprosthetic heart valve 
or valve repair.
Chronic kidney disease (CKD) was defined as 
estimated glomerular filtration rate (eGFR) < 60 mL/ 
/min/1.73 m2.
The group with heart failure (HF) consistent 
of patients with ejection fraction (EF) < 50%.
Anemia was defined as hemoglobin concentra-
tion less than 13 mg/dL in males and 12 mg/dL in 
females.
Ischemic heart disease (IHD) was defined as 
significant stenosis on coronary angiography or 
history of myocardial infarction (MI).
Statistical analysis
Data are expressed as means and standard de-
viations. Relative frequencies are used to present 
categorical variables. The Student’s t-test or the 
Wilcoxon rank-sum test was used for statistical 
analysis where applicable. The Kruskal-Wallis 
test or c2 test were used to describe differences 
between different types of AF. Logistic regression 
and multinomial logistic regression was used to 
evaluate the association between variables and 
in-hospital mortality. A p value of less than 0.05 
was considered statistically significant. The sta-
tistic software, StataIC (data analysis of statistical 
software) version 13, was used.
Results
Baseline characteristics
A total of 1,556 patients with AF (700 women, 
45%; mean age 71 ± 11 years) were included in 
the analysis. Paroxysmal AF was present in 42% 
(n = 659), persistent in 17% (n = 260), perma-
nent in 41% (n = 637) of the patients. Valvular 
AF was observed in 5% (n = 71). Hypertension 
was present in 74% (n = 1,145), diabetes in 27% 
(n = 415), CKD in 31% (n = 474), IHD in 45% 
(n = 706) and chronic HF in 56% (n = 877) of the 
patients. The mean left ventricular EF assessed by 
echocardiography was 46 ± 14%, mean left atrium 
diameter was 45 ± 8 mm.
CHA2DS2-VASc (congestive heart failure, hy-
pertension, age ≥ 75, diabetes mellitus, prior stroke 
or transient ischemic attack, vascular disease, 
age 65 to 74, female) score in the population with 
non-valvular AF was 3.5 ± 1.7 and HAS-BLED 
(hypertension, abnormal renal/liver function, 
stroke, bleeding history or predisposition, labile 
international normalized ratio [INR], elderly, drugs/ 
/alcohol concomitantly) score was 2.4 ± 1.1.
In the study population, the in-hospital mor-
tality was 2% (n = 35), there were no differences 
between males and females (p = 0.07).
Clinical characteristics of the population and 
gender differences are shown in Table 1.
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Table 1. Clinical characteristics of the population and gender differences.
All patients (n = 1,556) Female (n = 700) Male (n = 856) P
Age [years] 71 ± 11 74 ± 9 69 ± 12 < 0.001
Age ≥ 75 years [%] 43 35 52 < 0.001
Body mass index [kg/m2] 29 ± 5 29 ± 5 29 ± 5 0.4
Heart rate [bpm] 81 ± 26 82 ± 25 81 ± 24 0.3
Bradycardia (< 60 bpm) 14 14 14 0.7
Tachycardia (> 100 bpm) 16 16 17 0.5
SBP [mm Hg] 130 ± 23 131 ± 24 130 ± 21 0.4
CHA2DS2-VASc score: 3.5 4.3 ± 1.5 2.9 ± 1.6 0.001
0 [%] 3 0 5 < 0.001
1 [%] 10 3 16 < 0.001
≥ 2 [%] 87 97 79 < 0.001
HAS-BLED score: 2.4 2.5 ± 1 2.3 ± 1.1 0.001
0 [%] 10 5 14 < 0.001
≥ 3 [%] 25 18 33 < 0.001
eGFR [mL/min/1.73 m2]: 74 ± 26 72 ± 28 75 ± 24 0.02
≥ 90 [%] 29 32 26 0.003
60–89 [%] 40 40 39
45–59 [%] 17 16 18
30–44 [%] 10 9 11
15–29 [%] 3 2 5
< 15 [%] 1 1 1
Left atrial diameter [mm] 45 ± 8 44 ± 8 46 ± 8 0.0004
Ejection fraction [%] 46 ± 14 49 ± 13 42 ± 14 < 0.001
Valvular AF [%] 5 4 6 0.08
Type of AF: 0.0004
Paroxysmal [%] 42 38 48
Persistent [%] 17 18 15
Permanent [%] 41 44 37
Co-morbidity:
No co-morbidity [%] 3 2 3 0.3
1 co-morbidity [%] 12 11 12 0.5
≥ 2 co-morbidity [%] 85 86 84 0.3
Hypertension [%] 74 70 78 < 0.001
Diabetes mellitus [%] 27 24 30 0.007
Ischemic heart disease [%] 45 48 42 0.03
Chronic heart failure [%] 56 55 58 0.2
Ejection fraction < 35% 25 32 16 < 0.001
Dilated cardiomyopathy [%] 7 11 2 < 0.001
Chronic kidney disease [%] 31 28 35 0.002
COPD [%] 7 8 4 < 0.001
Anemia [%] 29 28 29 0.9
Hypothyroidism [%] 3 2 5 0.002
Hyperthyroidism [%] 2 2 3 0.01
Peripheral artery disease [%] 3 4 1 < 0.001
Previous MI [%] 18 20 15 0.006
Previous TIA/stroke [%] 10 10 10 0.7
Previous PCI [%] 9 11 6 0.001
Previous CABG [%] 6 7 4 0.006
Pacemaker [%] 15 13 18 0.004
ICD/CRT [%] 5 7 2 < 0.001
Electrical cardioversion [%] 6 7 5 0.9
Pharmacological cardioversion:
Amiodarone [%] 4 4 3 0.5
Propafenone [%] 1 1 1 0.7
In-hospital mortality [%] 2 2 3.2 0.07
AF — atrial fibrillation; CABG — coronary artery bypass graft; COPD — chronic obstructive pulmonary disease; CRT — implanted cardiac re-
synchronization device; eGFR — estimated glomerular filtration rate; ICD — implantable cardioverter defibrillator; MI — myocardial infarction; 
PCI — percutaneous coronary interventions; SBP — systolic blood pressure; TIA — transient ischemic attack
298 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 3
Prevalence of co-morbidities in  
different types of AF
Out of 1,556 patients, 3% were diagnosed to 
have only AF with no co-morbidity, 12% had one 
co-morbidity and 85% two or more co-morbidities. 
Among patients without co-morbidities or with one 
co-morbidity, paroxysmal type of AF was prevalent 
(p = 0.003, p = 0.006, respectively).
The CHA2DS2-VASc score in non-valvular AF 
population was the highest in permanent type of AF 
(p < 0.001) and the HAS-BLED score was the high-
est in paroxysmal and permanent AF (p < 0.001).
We observed several significant differences be-
tween patients with paroxysmal and permanent AF. 
Those with paroxysmal type had higher eGFR, small-
er left atrium (p < 0.001), higher EF (p < 0.001), 
less patients with HF with EF < 35% (p < 0.001), 
less patients with valvular AF (p = 0.004).
Clinical characteristics of patients with differ-
ent types of AF are shown in Table 2.
The cause of admission
The more common cause of admission were 
scheduled procedures (62%, coronary angiography, 
ablation and pacemaker implantation), less fre-
quently acute coronary syndromes (14%). Among 
patients with MI paroxysmal type of AF was most 
common (p < 0.001). Permanent AF was more 
often observed in patients admitted due to exacer-
bation of chronic HF (p < 0.001) (Table 3).
Stroke risk factors
The CHA2DS2-VASc score ≥ 2 was found in 
the majority of non-valvular AF patients. Perma-
nent type of AF was associated with the highest 
thromboembolic risk (p < 0.001) and was most 
commonly observed in patients with valvular AF 
(p = 0.004) (Table 4).
Antithrombotic therapy at discharge
Out of 1,537 (99%) patients who had CHA2DS2- 
-VASc score ≥ 2.71% received antithrombotic 
therapy. Among patients who did not require an-
ticoagulation (n = 19, CHA2DS2-VASc score = 0) 
7 received oral anticoagulation.
Antiplatelet drug was given in 39% of the 
patients. Out of this group 21% of patients had 
both acetylsalicylic acid (ASA) and oral antico-
agulation and 18% (n = 277) ASA as the only 
antithrombotic treatment. Thirty-four percent 
out of the population treated with ASA were 
diagnosed previously with IHD. ASA alone was 
the most common treatment in paroxysmal type 
of AF (p < 0.001) (Table 5).
Comparison of patients with  
valvular and non-valvular AF
Patients with valvular AF were older (p < 0.001), 
had higher systolic blood pressure and INR on admis-
sion (p < 0.001, p = 0.03, respectively). They had 
more often permanent type of AF (p < 0.004), anemia 
(p = 0.005) and lower EF (p < 0.001). The his-
tory of hypertension, IHD and previous MI was 
observed less frequently in valvular AF patients 
(p = 0.002, p = 0.006, p = 0.03, respectively) 
but they underwent coronary artery bypass graft 
(CABG) more often (p < 0.001).
The mean eGFR evaluated by MDRD formula 
was 74 ± 26 mL/min./1.73 m2 in patients with 
non-valvular AF and 73 ± 28 mL/min./1.73 m2 in 
patients with valvular AF (p = 0.002). CKD was 
observed with similar frequency (p = 0.35).
Valvular AF patients were significantly more 
often prescribed antithrombotic therapy (p = 0.001).
Comparison between the two groups is shown 
in Table 6.
In-hospital mortality
The in-hospital mortality did not significantly 
differ between patients with valvular and non-valvular 
AF (p = 0.3). Thirty-nine percent of the patients died 
of HF, 30% died of MI, 13% died of aortic stenosis, 
3% died of pulmonary embolism, 3% died of stroke, 
3% died of sepsis and 9% died of other reasons.
In the logistic regression model, odds of in-
hospital death were 4.6 times higher for patients 
> 75 years old (p < 0.001, 95% CI 2.08–10.21) and 
6.4 times higher if left ventricular EF was < 35% 
(p < 0.001, 95% CI 2.84–14.41). Of all co-mor-
bidities diabetes (OR = 2.36, p = 0.012, 95% CI 
1.20–4.64), CKD (OR = 2.73, p = 0.006, 95% CI 
1.33–5.59) and anemia (OR = 3.11, p = 0.002, 95% 
CI 1.52–6.36) were significantly associated with 
in-hospital mortality.
In multivariate logistic regression, odds of in-
hospital death were higher for patients > 75 years 
old (OR = 6.26, p = 0.001, 95% CI 2.06–19.02) and 
with EF < 35% (OR = 5.25, p < 0.001, 95% CI 
2.24–12.32) (Table 7).
Discussion
Recently, several population-based studies and 
registries have provided information on the inci-
dence, prevalence, and outcome of AF population 
[6, 7, 10–12]. However, there are no data regarding 
the characteristics of AF patients in Poland. We 
report the first results from the Cardiology Refer-
ence Center.
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Table 2. Clinical characteristics of patients with different types of atrial fibrillation.
Paroxysmal AF  
(n = 659)
Persistent AF  
(n = 260)
Permanent AF  
(n = 637)
P
Age [years] 71 ± 11 67 ± 11 73 ± 10 0.001
Age ≥ 75 years [%] 41 30 50 0.001
Female [%] 49 60 59 0.0004
Body mass index [kg/m2] 29 ± 5 29 ± 5 29 ± 5 0.7
Heart rate [bpm] 80 ± 25 88 ± 26 80 ± 23 0.001
Bradycardia (< 60 bpm] 16 10 14 0.09
Tachycardia (> 100 bpm) 17 22 14 0.01
SBP [mm Hg] 132 ± 23 128 ± 21 130 ± 23 0.05
CHA2DS2-VASc score: 3.5 ± 1.7 2.9 ± 1.8 3.6  ± 1.6 0.001
0 [%] 3 7 1 < 0.001
1 [%] 11 16 8 0.02
≥ 2 [%] 86 77 91 < 0.001
HAS-BLED: 2.5  ± 1.1 2.0  ± 1.1 2.4  ± 1.1 0.001
0 [%] 2 8 3 < 0.001
≥ 3 [%] 50 30 43 < 0.001
eGFR [mL/min/1.73 m2]: 76 ± 26 76 ± 26 70 ± 26 0.001
≥ 90 [%] 31 30 27 0.0003
60–89 [%] 43 43 34
45–59 [%] 13 14 23
30–44 [%] 9 8 11
15–29 [%] 3 3 4
< 15 [%] 1 1 1
International normalized ratio 1.4 ± 1 1.8 ± 1 1.7 ± 1
International normalized ratio > 3.5 3 7 6 0.009
Left atrial diameter [mm] 42 ± 6 45 ± 7 50 ± 9 0.001
Ejection fraction [%] 49 ± 13 46 ± 14 42 ± 14 0.001
Valvular AF [%] 3 4 7 0.004
Co-morbidity:
No co-morbidity [%] 3 6 2 0.003
1 co-morbidity [%] 12 17 9 0.006
≥ 2 co-morbidity [%] 84 78 89 0.00003
Hypertension [%] 78 65 73 0.0003
Diabetes mellitus [%] 27 22 28 0.2
Ischemic heart disease [%] 49 34 46 0.0003
Chronic heart failure [%] 57 60 54 0.3
Ejection fraction < 35% 17 24 33 < 0.001
Dilated cardiomyopathy [%] 4 6 11 < 0.001
Chronic kidney disease [%] 26 27 39 < 0.001
COPD [%] 7 6 8 0.6
Anemia [%] 31 21 30 0.006
Hypothyroidism [%] 4 2 4 0.4
Hyperthyroidism [%] 2 3 2 0.9
Peripheral artery disease [%] 4 2 3 0.3
Previous MI [%] 22 14 16 0.005
Previous TIA/stroke [%] 10 7 12 0.09
Previous PCI [%] 9 7 10 0.4
Previous CABG [%] 4 7 7 0.1
Pacemaker [%] 16 6 19 < 0.001
ICD/CRT [%] 3 5 7 0.0007
Electrical cardioversion [%] 2 30 1 < 0.001
Pharmacological cardioversion:
Amiodarone [%] 5 8 0 < 0.001
Propapafenone [%] 1 2 0 0.002
In-hospital mortality [%] 2 3 2 0.8
Abbreviations as in Table 1.
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AF is associated with a variety of cardiovas-
cular conditions and frequently coexists with HF, 
both leading to increased mortality [7, 13]. In con-
sequence, AF population remains a heterogenous 
group due to variety of clinical presentations and 
treatment options. In most of the reports and 
registries, AF is associated with at least one con-
comitant condition, most commonly with hyperten-
sion [6, 7]. In our population, 97% of AF patients 
had at least one associated medical condition. 
Approximately half of the AF patients suffered 
from coronary artery disease or HF. Every third 
person was obese, had diabetes or anemia. These 
findings are consistent with the data from Euro 
Heart Survey study where 90% of the patients had 
concomitant co-morbidities, with hypertension as 
the most prevalent co-morbidity [13].
Classification of AF into different types is useful 
in clinical practice and is associated with different 
therapy approach. There are only few studies show-
ing differences in characteristics and management 
of patients with different types of AF [7]. In our 
study, the most common AF type was paroxysmal 
AF, similarly as in RAFTING registry from Greece 
Table 3. The cause of admission.
All patients  
(n = 1,556)
Paroxysmal AF 
(n = 659)
Persistent AF 
(n = 260)
Permanent AF 
(n = 637)
P
Atrial fibrillation [%] 5 3 18 2 < 0.0001
Acute coronary syndrome: 14 17 10 12 < 0.0001
Unstable angina [%] 3 3 1 3
NSTEMI [%] 6 8 5 5
STEMI [%] 5 6 4 4
Exacerbation of CHF [%] 8 4 7 12
Acute heart failure [%] 3 2 3 3
Pulmonary embolism [%] 1 2 2 1
Schedule procedure: 58 59 55 60 < 0.0001
Pacemaker implantation [%] 7 5 1 10
Ablation [%] 1 3 1 0
Coronary angiography [%] 51 51 53 50
Other [%] 10 12 6 10 < 0.0001
CHF — chronic heart failure; NSTEMI — non ST elevation myocardial infarction; STEMI — ST elevation myocardial infarction
Table 4. Stroke risk factors.
Paroxysmal AF  
(n = 659)
Persistent AF  
(n = 260)
Permanent AF  
(n = 637)
P
Age ≥ 75 years [%] 41 30 50 < 0.001
Hypertension [%] 78 65 73 0.0003
Diabetes mellitus [%] 27 22 28 0.2
Coronary artery disease [%] 49 34 46 0.0003
Chronic heart failure [%] 57 60 54 0.3
Ejection fraction < 35% 17 24 33 < 0.001
Peripheral artery disease [%] 4 2 3 0.3
Previous MI [%] 22 14 16 0.005
Previous TIA/stroke [%] 10 7 12 0.09
CHA2DS2-VASc score ≥ 2 86 77 91 < 0.001
Valvular AF [%] 3 4 7 0.004
Abbreviations as in Table 1.
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Table 5. Antithrombotic therapy at discharge.
All patients  
(n = 1,538)
Paroxysmal AF  
(n = 652)
Persistent AF  
(n = 257)
Permanent AF  
(n = 629)
P
Antithrombotic therapy [%] 71 61 80 79 < 0.001
Vitamin K antagonists [%] 59 49 59 70 < 0.001
Warfarin [%] 27 26 33 25 0.4
Acenocumarol [%] 32 23 26 45 < 0.001
NOAC [%] 12 12 21 9 < 0.001
Dabigatran [%] 5 4 12 3 < 0.001
Rivaroxaban [%] 7 8 9 6 0.1
Antiplatelet therapy [%] 39 48 33 34 < 0.001
ASA + VKA [%] 19 18 20 21 < 0.001
ASA + NOAC [%] 2 2 3 2 < 0.001
ASA without OAC [%] 18 28 10 11 < 0.001
No antithrombotic therapy [%] 29 39 21 21 < 0.001
AF — atrial fibrillation; ASA — acetylsalicylic acid; NOAC — new oral anticoagulants; OAC — oral anticoagulation; VKA — vitamin K antagonists
[14], but in contrast to AFNET and PREFER reg-
istry were most common type was permanent type 
[7, 8]. Nieuwlaat et al. [13] showed that patients 
with permanent AF were older, had more often HF, 
valvular heart disease, diabetes and previous stroke/ 
/transient ischemic attack. There were no differ-
ences in prevalence of coronary artery disease, CKD 
or history of MI and CABG/percutaneous coronary 
intervention [13]. Consistent data were published in 
the Registry of German Competence NETwork on 
Atrial Fibrillation (AFNET) [7]. In our population, 
prevalence of co-morbidities, such as hypertension, 
diabetes, IHD, chronic HF and anemia is similar in 
patients with paroxysmal and permanent AF. These 
findings are contrary to studies mentioned above, 
in which paroxysmal AF population had less often 
concomitant conditions.
Sex differences in the epidemiology and clini-
cal management of AF are evident and have been 
described in several studies [6, 15, 16]. In this 
analysis, we found that females were older, had 
more often IHD, severely impaired EF, previous 
MI and CABG. These results differ from the Euro 
Observational Research Programme on Atrial 
Fibrillation (EORP-AF) where females had more 
non-ischemic HF and HF with preserved EF [6]. 
Similarly in Euro Heart Survey on Atrial Fibril-
lation females had more co-morbidities including 
HF with preserved EF [17]. Secondly, in our study, 
female patients had more often a permanent type 
of AF. The prevalence of valvular AF was similar 
in both genders. These results also differ from 
the EORP-AF and Euro Heart Survey studies 
where valvular AF was found more frequently in 
females, but there were no differences in type of 
AF between males and females [6, 16].
To date information on valvular AF is very 
scant. The prevalence of valvular AF in Europe 
according to PREFER registry varies from 1.9% 
to 5.4% [8]. In our population, valvular AF was 
present in 5% of the patients, similarly as in Spain 
and France. Patients with valvular AF were older, 
had more often a permanent type of AF, anemia 
and lower EF. The history of hypertension, coro-
nary artery disease and previous MI was observed 
less frequently in valvular AF patients but they 
underwent CABG more often. CKD was recorded 
with similar frequency. Valvular AF patients were 
significantly more often prescribed antithrombotic 
therapy. To our knowledge there have been no stud-
ies focusing on characteristics and management of 
patients with valvular AF so far.
Antithrombotic treatment is the hottest topic 
concerning AF nowadays. Our data were consist-
ent with data from Italy, where 70% of patients 
were given such a therapy. Different results were 
reported in France, Spain and Germany where 
antithrombotic treatment was used in 90%, 87.9% 
and 87.4%, respectively. There were no significant 
differences between the use of new oral anticoagu-
lants (NOAC) between Poland (12%), Germany 
(11.6%) and Spain (11.2%). In France, NOAC were 
used half as frequently. Surprisingly, in such 
a Western European country as Italy the rate of use 
of NOAC was extremely low (0.3%), much lower 
than in Poland [8].
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Table 6. Comparison of patients with valvular and non-valvular atrial fibrillation.
Non-valvular AF Valvular AF P
Age [years] 71 ± 11 68 ± 9 < 0.001
Age ≥ 75 years [%] 44 24 0.001
Female [%] 45 55 0.08
Body mass index [kg/m2] 29 ± 5 28 ± 4 0.9
Heart rate [bpm] 81 ± 25 83 ± 25 < 0.001
Bradycardia (< 60 bpm) 14 12 0.5
Tachycardia (> 100 bpm) 17 16 0.9
SBP [mm Hg] 131 ± 22 128 ± 27 < 0.001
eGFR [mL/min/1.73 m2]: 74 ± 26 73 ± 28 0.002
≥ 90 [%] 30 32 0.4
60–89 [%] 40 32
45–59 [%] 17 17
30–44 [%] 9 16
15–29 [%] 3 3
< 15 [%] 1 0
International normalized ratio 1.53 ± 1.0 2.67 ± 1.77 0.03
Left atrial diameter [mm] 45 ± 8 54 ± 10 0.7
Ejection fraction [%] 46 ± 14 44 ± 16 < 0.001
Type of AF: 0.004
Paroxysmal [%] 43 25
Persistent [%] 17 15
Permanent [%] 40 60
Co-morbidity:
No co-morbidity [%] 3 3 0.9
1 co-morbidity [%] 12 15 0.3
≥ 2 co-morbidity [%] 85 82 0.3
Hypertension [%] 74 58 0.002
Diabetes mellitus [%] 23 31 0.4
Ischemic heart disease [%] 46 30 0.006
Chronic heart failure [%] 56 60 0.4
Ejection fraction < 35% 24 32 0.1
Dilated cardiomyopathy [%] 7 10 0.4
Chronic kidney disease [%] 31 36 0.35
COPD [%] 7 7 0.97
Anemia [%] 28 43 0.005
Hypothyroidism [%] 3 1 0.3
Hyperthyroidism [%] 2 6 0.6
Peripheral artery disease [%] 3 0 0.1
Previous MI [%] 19 8 0.03
Previous TIA/stroke [%] 10 11 0.7
Previous PCI [%] 9 8 0.8
Previous CABG [%] 5 21 < 0.001
Pacemaker [%] 15 22 0.09
ICD/CRT [%] 5 7 0.4
Electrical cardioversion [%] 6 4 0.5
Pharmacological cardioversion:
Amiodarone [%] 4 4 0.8
Propapafenone [%] 1 1 0.7
Antithrombotic therapy [%] 70 85 0.01
No antithrombotic therapy [%] 27 11
Unknown [%] 3 4
Vitamin K antagonists [%] 58 84
New oral anticoagulants [%] 12 1
Only aspirin [%] 19 3 0.001
In-hospital mortality [%] 2 4 0.3
Abbreviations as in Table 1.
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Table 7. Multivariate logistic regression.
Odds of in-hospital death Odds ratio 95% confidence interval P
Age ≥ 75 years 6.26 2.06–19.02 0.001
Anemia 1.97 0.84–4.59 0.1
Chronic kidney disease 0.86 0.36–2.03 0.7
Ejection fraction < 35% 5.25 2.24–12.32 < 0.001
Diabetes mellitus 1.72 0.73–4.06 0.2
Population-based studies have indicated AF 
to be an independent predictor of increased late 
mortality [18]. Data from the Framingham study 
demonstrated a 1.5- to 1.9-fold risk of mortality in 
patients with AF in both males and females across 
a wide range of ages after adjustment for preexisting 
cardiovascular diseases [19].
Swedish nation-wide long-term case-control 
study showed the same finding in patients hospital-
ized with incident AF. The concomitant diseases 
that contributed most to an increased mortality 
were neoplasm, chronic renal failure and chronic 
obstructive airway disease. It is worth noting that 
none of these diseases are included in CHA2DS2- 
-VASc score [12].
The relationship between mortality and type 
of AF remains unclear. Actually, there is no infor-
mation on connections of various types of AF with 
all-cause mortality. For example, Swedish registry 
data did not allow differentiation between parox-
ysmal, persistent and permanent type of AF [12]. 
It is likely that on follow-up some of the patients 
progressed to permanent type of AF. For example, 
in the Loire Valley AF Project, only permanent 
type of AF was associated with increased mortality 
[17]. Our data on mortality concerns only short-
term follow-up what is why the analysis of types 
is possible, because the percentage of patients 
who progressed to permanent type was low. In 
our population, the in-hospital mortality was 2% 
and did not differ between patients with valvular 
and non-valvular AF. Of all co-morbidities only dia-
betes, CKD and anemia had impact on in-hospital 
mortality. However, the independent predictors of 
death were age > 75 years and EF < 35%.
Limitations of the study
We have no current data on treatment strate-
gies for the prevention of AF. Outpatient centers 
did not contribute for this registry and patients 
cared for by general practitioners were not in-
cluded. This has to be taken into account when 
extrapolating from these data to the general popula-
tion. No patients with AF were admitted because 
of a stroke, and only 5% were admitted due to AF. 
These evidences point out a selection bias, prob-
ably a referral to a Cardiology and Interventional 
Department of a high complexity Hospital.
Multiple logistic regression requires 10 to 
15 events per variable analyzed. Since there were only 
31 deaths, the model obtained is not a solid evidence.
Conclusions
AF originates from various substrates and, 
as a consequence, the AF population remains het-
erogeneous group. Most patients included in our 
registry have at least one comorbidity, most com-
monly hypertension. Our population with AF have 
similar risk of ischemic stroke and bleeding as in 
European registries. The need for anticoagulation 
in AF patients is well established in daily medical 
care in Poland, similarly to Western Europe. Patients 
with valvular AF are more frequently prescribed an-
tithrombotic therapy than patients with non-valvular 
AF. In our study, paroxysmal AF population is similar 
to permanent AF population while in other regis-
tries permanent AF population correlates with HF 
more frequently. In-hospital mortality is relatively 
low in both valvular and non-valvular AF patients 
and connected with old age and left ventricular HF.
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